FIGURE 7.
Proposed model. Hypoxia results in the release of EGF from pulmonary endothelial cells, which can then activate EGFR on the pulmonary vascular smooth muscle cells (SMCs) leading to induction of Arg2 which results in pulmonary vascular SMC proliferation. Antibodies against EGF or EGFR, or antagonists of Arg2, may be potential therapeutics in preventing hypoxia‐induced pulmonary vascular remodeling.